Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Indian pharma firms expect modest growth amid margin pressure.
Indian pharma companies expect modest sales growth of 11% in the March quarter, driven by a strong domestic market.
However, HDFC Securities predicts a 110 basis point drop in EBITDA margins due to rising costs, US pricing pressure, and the absence of key drugs like gRevlimid.
The hospital and retail pharmacy sectors are projected to grow significantly, while diagnostics also show robust performance.
6 Articles
Las firmas farmacéuticas indias esperan un crecimiento modesto en medio de la presión de los márgenes.